

Reduction of inappropriate shock rate through signal filtering (smart-pass) in patients with implantable subcutaneous cardioverter-defibrillator: a systematic review and meta-analysis

Maurizio Santomauro,¹ Mario Petretta,¹ Carla Riganti,² Mario Alberto Santomauro,³ Mariarosaria De Luca,⁴ Andrea Santomauro,⁵ Antonio Cittadini⁴

¹IRCCS SYNLAB SDN, Naples; ²Department of Health Services, Federico II University, Naples; ³Department of Pharmacy, Sant'Ottone Frangipane Hospital, Ariano Irpino; ⁴Department of Translational Medical Sciences, Federico II University, Naples; ⁵Emergency Medicine and Critical Care Medicine Department, Vita-Salute San Raffaele University, Milan, Italy

Correspondence: Maurizio Santomauro, IRCCS SYNLAB SDN, Naples, Italy.
Tel.: +39 330502275.
E-mail: santomau@unina.it

Key words: subcutaneous implantable cardioverter defibrillator, inappropriate shock, oversensing, malfunctions, sudden death.

Contributions: all authors have contributed significantly, agreed with the content of the manuscript, and approved its final version. MS, experiments concept and design; MP, statistical analysis; CR, experiments performing; MAS, analysis of references; MDEL, interpretation of experiments results; AS, analysis and interpretation of experiments results; AC, analysis and interpretation of experiments results.

Conflict of interest: the authors declare that no conflict of interest.

Ethics approval and consent to participate: the committee assessed the planned project as ethically unobjectionable.

Informed consent: not applicable.

Patient consent for publication: not applicable.

Availability of data and materials: the datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding: none.

Received: 2 April 2024.

Accepted: 19 May 2024.

Early view: 29 August 2024.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2025; 95:3013

doi: 10.4081/monaldi.2024.3013

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Subcutaneous implantable cardioverter-defibrillators (S-ICD) are effective in protecting patients against sudden death but expose them to a higher risk of inappropriate shock (IAS). We performed a systematic search of studies published between January 2010 and December 2019 assessing IAS due to cardiac oversensing by the selection process (PRISMA) and identified 17 eligible articles. A total of 15 studies were observational, and 2 were retrospective. For the meta-analysis, the final population included 6111 patients: 3356 without the SMART-pass (SP) filter (group 1) and 2755 with the SP filter (group 2). A total of 1614 shocks (appropriate shocks plus IAS) were registered (1245 in group 1 and 369 in group 2). The random effects meta-analysis estimated an overall IAS rate of 7.78% (95% confidence interval: 4.93-10.64) with substantial variability between studies ($I^2=96.05\%$, $p<0.001$). The IAS rate was 10.75% (95% confidence interval: 8.49-13.02) for group 1 and 3.61% (95% confidence interval: 1.36-5.86) for group 2 ($p<0.001$). Third-generation S-ICD technology with SP filters reduced the risk of cardiac signal-related IAS.

Introduction

Cardiovascular mortality, as a consequence of ventricular fibrillation or ventricular tachycardia (VT), represents a significant health problem despite advances in the management of cardiovascular disease. Worldwide, survival after the out-of-hospital cardiac arrest remains poor. These survivors have different therapeutic options such as anti-arrhythmic drugs, radiofrequency or surgical ablation, or implantable cardioverter-defibrillators (ICD). Nowadays, recently introduced subcutaneous ICD (S-ICD) systems are a good alternative to the implant of transvenous ICD (T-ICD) for the prevention of sudden cardiac death in patients with recurrent monomorphic VT responsive to antitachycardia pacing, or pre-existing unipolar pacemaker leads, and without indication for anti-bradycardia pacing or cardiac resynchronization therapy. Moreover, high risk of infections, congenital heart disease, and poor vascular access are strong determinants for the appropriate device selection [1,2]. It seems to be helpful for younger patients with cardiomyopathies or channelopathies in primary prevention [3,4]. Although initial reports indicated an acceptable rate of inappropriate shock (IAS) on patients with S-ICD [5,6], novel mechanisms of noise oversensing have recently been reported [7,8]. In this study, we performed a systematic review and meta-analysis on the occurrence of

IAS in patients with S-ICD implanted from 2010 to 2019 with and without the SMART-pass (SP) filter.

Materials and Methods

Search strategy

The systematic search to identify articles with S-ICD IAS rates was limited between January 1, 2010, to December 31, 2019 by three investigators, in the following database: PubMed, Embase.com (Elsevier), the Cochrane Library (Wiley), CRD (Centre for Reviews and Dissemination): DARE (Database of Abstracts of Reviews of Effects), and HTA (Health Technology Assessment Database). The article type was limited to “clinical trial”. The following Boolean search terms were utilized: “subcutaneous implantable defibrillator or S-ICD” and “shocks or therapy”, “inappropriate” and “cardiac oversensing”. By hand-search, records identified through database searching yielded a total of 730 citations.

Study selection and data extraction

Overall, 610 citations were identified after the removal of duplicates. The references were screened by two independent researchers (SMA and CF), and, in case of disagreement, a third researcher (IL) was involved to resolve the differences. The selection process (PRISMA flow diagram) is displayed in Figure 1 [9]. Search criteria and methodology were approved by all authors. Titles and abstracts retrieved in the search were reviewed, and observational and comparative studies reporting IAS rates in S-ICD were selected. Case reports, review articles, abstracts, meta-analyses, and editorials were excluded. If there were multiple publications from the same study, the latest study with the most complete data available was selected, and the other publications were not used to avoid overlapping cohorts. Because randomized controlled trials (RCTs) and non-RCTs were included in this meta-analysis, we used the Jadad scale to assess the quality of the RCTs, whereas the methodological index

for non-randomized studies (MINORS) scale was used to assess non-RCTs [10]. If two independent evaluations conflicted, all authors participated in a discussion to resolve the controversy. For included studies, only data on S-ICD patients were extracted. Extracted data included: SP filter, patients' mean age, number of total shocks delivered, follow-up (FU) duration, and IAS. Data were extracted by one author and were reviewed by additional authors.

Statistical analysis

Continuous variables were expressed as mean $\pm$ standard deviation, and categorical data as percentages. Differences between groups were analyzed by *t*-test or chi-square test, as appropriate. The main effect size of the study was the proportion of patients experiencing IAS during FU (also referred to in the text as IAS rate). The user-written Stata meta prop-one package was used to pool proportions and to present weighted sub-group and overall estimates with inverse-variance weights [11]. For this purpose, the random-effects model with the logit transformation was applied, and the result was displayed as a forest plot. Study-specific 95% confidence intervals were calculated using the Clopper-Pearson exact method. Between-study heterogeneity was evaluated with Cochran's *Q*, and I^2 statistics. When statistical heterogeneity was substantial, meta-regression analysis was performed to identify potential confounders (namely, SP filter, patients' mean age, number of total shocks delivered, FU duration). The IAS rate was modeled on the log scale as a linear combination of the regression factors, and *p*-values <0.05 were considered statistically significant. Statistical analysis was performed using the Stata software 16.0 (StataCorp 4905 Lakeway Drive, College Station, TX, USA). The presence of publication bias was graphically assessed using a funnel plot, a simple graphical display of a measure of study size against the logit of the IAS rate. The interpretation of funnel plots is facilitated by the inclusion of diagonal lines representing the 95% confidence limits around the summary treatment effect, showing the expected distribution of studies in the absence of bias [12]. Because these diagonal lines are not strict 95% limits but rather a region in which 95% of the observed effects are expected to fall if the true effects are homogeneous, they are referred to as “pseudo 95% confidence limits”. To evaluate potential publication bias, the test proposed by Egger et al was also performed [13].

Results

After excluding 580 articles for not meeting inclusion/exclusion criteria, 30 articles remained to be assessed for eligibility. Following assessment of the full-text articles, 13 were excluded because shocks were not specified or rates of inappropriate therapy, rather than just shocks, were given. A total of 17 studies were included in the analysis [2,3,5,6,8,14-25] (Table 1). The final population for the meta-analysis included 6111 patients, 3356 without SP filter (Group 1) and 2755 with SP filter (Group 2). Years of enrolment for the studies ranged from 2010 to 2019 (median 2016); 15 studies were observational, and 2 were retrospective. One study enrolled patients in a remote monitoring system (LATITUDE). Shock incidence was calculated for patients with SP program enabled (SMART-pass ON) or disabled (SMART-pass OFF) at implantation, censoring patients when SP programming changed or at the last transmission. The total number of appropriate shocks plus IAS was 1614, 1245 in group 1, and 369 in group 2. The random effects meta-analysis estimated an overall IAS rate of 7.78% [95% confidence interval (CI) 4.93-




Figure 1. Flow-chart of study selected (PRISMA flow diagram).

Table 1. The selected S-ICD studies that investigate the inappropriate shocks in chronological order.


Authors	Year	N pts	Age (years)	Follow-up (months)	Shock	% IAS
Bardy <i>et al.</i> [5]	2010	55	61±11	10±1	16	9
Dabiri Abkenari <i>et al.</i> [14]	2011	31	53±16	13.9±2.5	37	9.6
Aydin <i>et al.</i> [15]	2012	40	42±15	19±17	30	5
Olde Nordkamp <i>et al.</i> [6]	2012	118	50±14	18±7	60	13
Jarman, Todd [17]	2013	111	33 (10-87)	13±7	75	15
Kobe <i>et al.</i> [3]	2013	69	46±16	18±11	6	5.4
Burke <i>et al.</i> [2]	2015	882	50±16.9 (7-88)	54±28	328	13.1
Olde Nordkam <i>et al.</i> [16]	2015	581	49±18	21±13	101	8.3
Brouwer <i>et al.</i> [18]	2016	140	41±39	60±1	32	20.5
Gold <i>et al.</i> [19]	2017	1637	52±15	1±1	3	0.2
Ozkartal <i>et al.</i> [20]	2017	37	47±15	3.7	3	5.4
Honarbakshsh <i>et al.</i> [21]	2017	69	35±13	31±19	6	4.3
Mithani <i>et al.</i> [22]	2018	91	54±13	3±3	2	1.1
Theuns <i>et al.</i> [8]	2018	1984	48±16	16±6	880	9.7 vs. 4.3
Migliore <i>et al.</i> [23]	2019	44	37±17	12±13	13	2.9
Khazen <i>et al.</i> [24]	2019	79	44.5±17.2	12.8±13.7	13	8.9
Liang <i>et al.</i> [25]	2019	86	45±16	23±14	9	9.3

IAS, inappropriate shocks; pts, patients.

Table 2. Results of multivariable meta-regression analysis.

IAS rate	Coefficient	SE; T-value	p>t	P>t	95% CI
Group	-0.0539472	0.012617; -4.28	0.001	-0.0812046	-0.0266898
Age (years)	-0.0014142	0.0009994; -1.42	0.181	-0.0035733	0.0007448
Shocks delivered	0.0000196	0.0000262; 0.75	0.468	-0.000037	0.0000762
Follow-up (months)	0.0013331	0.0003912; 3.41	0.005	0.0004879	0.0021783
Cons	0.1308092	0.0545776; 2.40	0.032	0.0129014	0.248717

IAS rate, absolute rate of inappropriate shocks; SE, standard error; CI, confidence interval; cons, constant.

**Figure 2.** Meta-analysis of the patients with inappropriate shocks without the SMART pass group and with the SMART Pass group in the selected subcutaneous implantable cardioverter-defibrillator studies.

10.64] with substantial variability between studies ($I^2=96.05\%$, $p<0.001$) (Figure 2). The IAS rate was 10.75% (95% CI 8.49-13.02) for group 1 and 3.61% (95% CI 1.36-5.86) for group 2 ($p<0.001$). Results of multivariable meta-regression analysis are reported in Table 2. As shown, SP filter group and FU length explained a significant degree of between-study variability ($p<0.001$), lowering the residual heterogeneity (I^2 residual 37.88%). The IAS rate was higher in group 1 than in group 2 and progressively increased with the length of FU. The funnel plot appears symmetrical (Figure 3), without evidence of bias using the Egger weighted regression method ($p=0.06$).

Discussion

To the best of our knowledge, this is the first meta-analysis evaluating the impact of SP filters on the incidence of IAS in a large number of patients who underwent S-ICD implantation. The results demonstrate that the IAS rate was significantly higher in the trials of S-ICD without SP filter as compared to the IAS rate of trials with SP filter. Indeed, the mean IAS rate for S-ICD without SP filter was 10.75%, ranging from 5.00% in the study by Aydin *et al.* to 20.71% in the study by Brouwer *et al.* [15,18]. Conversely, the mean IAS rate for S-ICD with SP filter was 3.61%, ranging from 0.18% in the




Figure 3. The funnel plot displays the study's inappropriate shock (IAS) rate on a logit scale against its standard error for each study included in the meta-analysis. The vertical line indicates the pooled estimate of the overall prevalence rate, with the diagonal lines representing the expected pseudo 95% confidence limits around the summary.

study by Gold *et al.* to 9.30% in the study of Liang *et al.* [19,25]. In previous studies on conventional T-ICD trials, the IAS rate ranged from 4% to 18% [3]. With modern devices and programming, these percentages dropped (2.8-3.7%) over the last 2 years [26,27].

IAS in S-ICD typically results from oversensing of cardiac signals [due to supraventricular arrhythmias (SVT) identified as ventricular arrhythmias] or due to noncardiac oversensing [7]. The introduction of automatic screening triggered (AST) in the pre-implant screening provided a progressive reduction of IAS and, in turn, proper patient selection. Appropriate patient selection and pre-implantation electrocardiogram (ECG) screening are probably the most effective ways to avoid oversensing-related IAS. Exercise testing during pre-implant ECG screening has been suggested to be useful in assessing vector eligibility in patients with hypertrophic cardiomyopathy [28]. Rudic *et al.* proposed the adoption of postoperative exercise screening to exclude oversensing of cardiac and noncardiac signals [29]. Furthermore, post-implant exercise may be executed to improve discrimination when rate-dependent variations in QRS morphology occur. In case of noise induction in the current vector, device reprogramming to a noise-free vector was done. In contrast, Larbig *et al.* analyzed the impact of ergometry-guided programming on primary and secondary prevention of T-wave oversensing (TWO) [30]. FU analyses did not reveal significant differences related to the control group (9.8% vs. 8.1%; $p=0.731$). The authors concluded that postoperative ergometry does not seem to be helpful for the prevention of cardiac oversensing.

Carefully optimized vector selection with device programming led to a further reduction in IAS. Indeed, programming and discrimination algorithms have evolved significantly. Dual zone (programming a 170-220 bpm zone with SVT discrimination algorithms plus a zone for heart rate >220 bpm) significantly decreased the rate of IAS [7]. Earlier studies showed a high rate of IAS of 7% per year for the first-generation S-ICD [5,6]. IAS were mainly attributed to TWO (39%) and SVT above the discrimination zone (24%), which could be lowered by dual-zone programming [6]. After the addition of the SP filter and additional

advancements, studies reported IAS rates of 3.5% to 6.4% annually, so that the risk of IAS with T-ICD and S-ICD becomes comparable [27]. Noteworthy, in our meta-analysis, IAS due to cardiac oversensing was 10.75% for group 1 and 3.61% for group 2 ($p<0.001$) (Figure 3). Both SP filter groups and FU length explained a statistically significant degree of between-study variability ($p<0.001$), lowering the residual heterogeneity to 37.88%. A limitation of this meta-analysis is the high heterogeneity between studies observed. However, at meta-regression analysis, SP filter group and FU length explained a significant degree of between-study variability, lowering the residual heterogeneity to 38%. Another limitation is the possible presence of publication bias. In fact, the funnel plots and the Egger weighted regression method may be inaccurate for meta-analyses of proportion studies with low proportion outcomes [13].

Conclusions

Data from clinical studies recommend that the S-ICD is useful to protect patients against sudden death and expose them to less risk of IAS than similar T-ICD patients. When interpreting the results of our review summary, it should be considered that the technology of third-generation S-ICD with SP filter and the development of AST have progressively reduced the risk of IAS related to cardiac signals, without eliminating the risk of IAS related to extracardiac signals. However, the current SP filter, incorporated in the S-ICD system, mitigates the impact of IAS while maintaining sensitivity and specificity in detecting VT. Therefore, it is essential in the Emergency Department to correctly identify different potential causes of IAS.

References

1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* 2018;15:e190-e252.
2. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. *J Am Coll Cardiol* 2015;65:1605-15.
3. Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. *Heart Rhythm* 2013;10:29-36.
4. Jarman JW, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. *Eur Heart J* 2012;33:1351-9.
5. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med* 2010;363:36-44.
6. Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. *J Am Coll Cardiol* 2012;60:1933-9.
7. Saini A, Ellenbogen KA. Oversensing and inappropriate shock in a patient with a subcutaneous implantable cardioverter defib-

- rillator: what is the mechanism?. *Pacing Clin Electrophysiol* 2017;40:897-9.
8. Theuns DAMJ, Brouwer TF, Jones PW, et al. Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. *Heart Rhythm* 2018;15:1515-22.
 9. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
 10. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg* 2003;73:712-6.
 11. Nyaga VN, Arbyn M, Aerts M. METAPROP: stata module to perform fixed and random effects meta-analysis of proportions. Available from: <https://www.gnu.org/licenses/gpl-3.0.txt>.
 12. Hunter JP, Saratzis A, Sutton AJ, et al. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J Clin Epidemiol* 2014;67:897-903.
 13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
 14. Dabiri Abkenari L, Theuns DA, Valk SD, et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. *Clin Res Cardiol* 2011;100:737-44.
 15. Aydin A, Hartel F, Schlüter M, et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience. *Circ Arrhythm Electrophysiol* 2012;5:913-9.
 16. Olde Nordkamp LR, Brouwer TF, Barr C, et al. Inappropriate shocks in the subcutaneous ICD: incidence, predictors and management. *Int J Cardiol* 2015;195:126-33.
 17. Jarman JW, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. *Europace* 2013;15:1158-65.
 18. Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. *J Am Coll Cardiol* 2016;68:2047-55.
 19. Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. *Heart Rhythm* 2017;14:1456-63.
 20. Özkartal T, Breitenstein A, Saguner AM, et al. The subcutaneous implantable cardioverter defibrillator in daily clinical practice. *Swiss Med Wkly* 2017;147:w14518.
 21. Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. *Int J Cardiol* 2017;228:280-5.
 22. Mithani AA, Kath H, Hunter K, et al. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement. *Europace* 2018;20:308-14.
 23. Migliore F, Mattesi G, De Franceschi P, et al. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique. *J Cardiovasc Electrophysiol* 2019;30:854-64.
 24. Khazen C, Magnusson P, Flandorfer J, Schukro C. The subcutaneous implantable cardioverter-defibrillator: a tertiary center experience. *Cardiol J* 2019;26:543-9.
 25. Liang JJ, Okamura H, Asirvatham R, et al. Comparative outcomes of subcutaneous and transvenous cardioverter-defibrillators. *Chin Med J (Engl)* 2019;132:631-7.
 26. Brouwer TF, Knops RE, Kutyla V, et al. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies. *Europace* 2018;20:f240-8.
 27. Auricchio A, Hudnall JH, Schloss EJ, et al. Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis. *Europace* 2017;19:1973-80.
 28. Afzal MR, Evenson C, Badin A, et al. Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator. *Heart Rhythm* 2017;14:1436-9.
 29. Rudic B, Tülümen E, Berlin V, et al. Low prevalence of inappropriate shocks in patients with inherited arrhythmia syndromes with the subcutaneous implantable defibrillator single center experience and long-term follow-up. *J Am Heart Assoc* 2017;6:e006265.
 30. Larbig R, Motloch LJ, Bettin M, et al. Device updates successfully reduce T-wave oversensing and inappropriate shocks in subcutaneous ICD patients. *Neth Heart J* 2018;26:606-11.